ATE450265T1 - Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält - Google Patents

Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält

Info

Publication number
ATE450265T1
ATE450265T1 AT02713967T AT02713967T ATE450265T1 AT E450265 T1 ATE450265 T1 AT E450265T1 AT 02713967 T AT02713967 T AT 02713967T AT 02713967 T AT02713967 T AT 02713967T AT E450265 T1 ATE450265 T1 AT E450265T1
Authority
AT
Austria
Prior art keywords
treatment
nucleoside analogues
cancer containing
dioxolane nucleoside
pharmaceutical mixture
Prior art date
Application number
AT02713967T
Other languages
German (de)
English (en)
Inventor
Francis J Giles
Hagop M Kantarjian
Jacques Jolivet
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Application granted granted Critical
Publication of ATE450265T1 publication Critical patent/ATE450265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT02713967T 2001-03-23 2002-03-25 Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält ATE450265T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27797501P 2001-03-23 2001-03-23
US33060101P 2001-10-25 2001-10-25
PCT/CA2002/000426 WO2002076472A2 (en) 2001-03-23 2002-03-25 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs

Publications (1)

Publication Number Publication Date
ATE450265T1 true ATE450265T1 (de) 2009-12-15

Family

ID=26958821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713967T ATE450265T1 (de) 2001-03-23 2002-03-25 Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält

Country Status (13)

Country Link
US (2) US6800639B2 (https=)
EP (1) EP1370270B1 (https=)
JP (1) JP4391087B2 (https=)
KR (1) KR20040018341A (https=)
AT (1) ATE450265T1 (https=)
CA (1) CA2441568A1 (https=)
DE (1) DE60234577D1 (https=)
HU (1) HUP0400314A3 (https=)
MX (1) MXPA03008623A (https=)
NO (1) NO20034204L (https=)
NZ (1) NZ528394A (https=)
PL (1) PL365285A1 (https=)
WO (1) WO2002076472A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
EP1545553B1 (de) * 2002-07-30 2011-07-13 Æterna Zentaris GmbH Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
CA2527126A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CA2845251A1 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008030373A2 (en) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L- oddc prodrugs for cancer
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
PL2252283T3 (pl) 2008-01-11 2019-09-30 Reata Pharmaceuticals, Inc. Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
US20100004193A1 (en) * 2008-07-07 2010-01-07 Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare Combination therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
MX357596B (es) 2010-04-12 2018-07-16 Reata Pharmaceuticals Inc Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes.
WO2014025961A1 (en) * 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
JP7337539B2 (ja) 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2023076036A1 (en) 2021-10-28 2023-05-04 Analiza, Inc. Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
KR20050005569A (ko) * 1999-03-29 2005-01-13 샤이어 바이오켐 인코포레이티드 백혈병 치료방법
AU1201502A (en) * 2000-10-13 2002-04-22 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine

Also Published As

Publication number Publication date
CA2441568A1 (en) 2002-10-03
NZ528394A (en) 2005-06-24
PL365285A1 (en) 2004-12-27
WO2002076472A3 (en) 2003-04-10
NO20034204D0 (no) 2003-09-22
HUP0400314A3 (en) 2006-02-28
NO20034204L (no) 2003-11-21
WO2002076472A2 (en) 2002-10-03
EP1370270B1 (en) 2009-12-02
JP4391087B2 (ja) 2009-12-24
KR20040018341A (ko) 2004-03-03
US20030083316A1 (en) 2003-05-01
JP2004525142A (ja) 2004-08-19
US6800639B2 (en) 2004-10-05
MXPA03008623A (es) 2004-05-21
EP1370270A2 (en) 2003-12-17
US20050004081A1 (en) 2005-01-06
HUP0400314A2 (hu) 2004-08-30
DE60234577D1 (de) 2010-01-14

Similar Documents

Publication Publication Date Title
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
SE0100568D0 (sv) Compounds
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
SE0100567D0 (sv) Compounds
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
GB0130677D0 (en) Medicaments and novel compounds
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
SE0100566D0 (sv) Compounds
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
SE0004101D0 (sv) New use
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.
SE0101692D0 (sv) Compounds
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
SE0004827D0 (sv) Therapeutic compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties